Show simple item record

dc.contributor.authorKapran, Yersu
dc.contributor.authorKilicaslan, Işın
dc.contributor.authorErbil, Yesim
dc.contributor.authorSenyurek, Yasemin Giles
dc.contributor.authorDizdaroglu, Ferhunde
dc.contributor.authorGulluoglu, Mine
dc.contributor.authorMete, Oezguer
dc.date.accessioned2021-03-04T18:42:27Z
dc.date.available2021-03-04T18:42:27Z
dc.date.issued2010
dc.identifier.citationMete O., Kapran Y., Gulluoglu M., Kilicaslan I., Erbil Y., Senyurek Y. G. , Dizdaroglu F., "Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas", VIRCHOWS ARCHIV, cilt.456, sa.5, ss.515-521, 2010
dc.identifier.issn0945-6317
dc.identifier.othervv_1032021
dc.identifier.otherav_8c1fcb4b-fc55-478e-9e80-6775448fd59a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/94813
dc.identifier.urihttps://doi.org/10.1007/s00428-010-0901-0
dc.description.abstractIn the evaluation of retroperitoneal masses, the practicing pathologist faces a dilemma when making a diagnosis based on histology given the often overlapping morphologic appearances of the adrenocortical carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). CD10 is expressed in a membranous fashion in the vast majority of clear cell RCCs; therefore, it is widely used for distinction from its mimics. However, its expression is not well-investigated in adrenal cortical tumors. We examined CD10 expression in 47 surgically resected adrenocortical tumors (26 adenomas and 21 carcinomas) and compared with 20 clear cell RCCs and 25 HCCs. Twenty HCCs (80%), 18 RCCs (90%), 11 adrenocortical carcinomas (52%), and 18 adrenocortical adenomas (69%) were positive for CD10. HCCs were characterized by a canalicular staining, and clear cell RCCs exhibited membranous or mixed membranous-cytoplasmic staining. Adrenocortical tumors displayed mainly cytoplasmic staining. Four adrenocortical carcinomas and one adenoma also displayed the membranous staining pattern. Despite the relatively small number of samples, our preliminary results revealed that adrenocortical tumors may express CD10 (Clone: 56C6). The most important point from this paper is the fact that anti-CD10 expression has not been previously reported in adrenocortical carcinomas. This suggests that CD10 does not seem to be a useful marker for discriminating clear cell RCCs from adrenocortical tumors since CD10 expression does not rule out the possibility of adrenocortical tumors. This feature should be kept in mind when constructing an antibody panel for an epithelial tumor that involves the adrenal gland and kidney, especially in small biopsy specimens.
dc.language.isoeng
dc.subjectPatoloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectHistology
dc.subjectPathology and Forensic Medicine
dc.subjectBiochemistry (medical)
dc.subjectHealth Sciences
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyokimya
dc.subjectCerrahi Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectBiyoloji ve Biyokimya
dc.subjectPATOLOJİ
dc.titleAnti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas
dc.typeMakale
dc.relation.journalVIRCHOWS ARCHIV
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume456
dc.identifier.issue5
dc.identifier.startpage515
dc.identifier.endpage521
dc.contributor.firstauthorID20257


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record